Leonard Patrick Gage Net Worth

The estimated Net Worth of L Patrick Gage is at least $2.15 Million dollars as of 8 November 2021. Leonard Gage owns over 26,468 units of Cytokinetics Inc stock worth over $1,779,679 and over the last 21 years he sold CYTK stock worth over $118,560. In addition, he makes $247,206 as Independent Chairman of the Board at Cytokinetics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Leonard Gage CYTK stock SEC Form 4 insiders trading

Leonard has made over 27 trades of the Cytokinetics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 26,468 units of CYTK stock worth $112,489 on 8 November 2021.

The largest trade he's ever made was exercising 26,468 units of Cytokinetics Inc stock on 8 November 2021 worth over $112,489. On average, Leonard trades about 3,358 units every 95 days since 2003. As of 8 November 2021 he still owns at least 33,098 units of Cytokinetics Inc stock.

You can see the complete history of Leonard Gage stock trades at the bottom of the page.

Leonard Patrick Gage biography

Dr. Leonard Patrick Gage is Independent Chairman of the Board of the Company. Dr. Gage has served as a member of our Board of Directors since November 2009 and as Chairman of the Board of Directors since March 2010. Since July 2002, Dr. Gage has served as a consultant to the biopharmaceutical industry, including serving as an advisor to venture capital firms. From 1998 to 2002, Dr. Gage was President of Wyeth Research and subsequently also Senior Vice President, Science and Technology for American Home Products Corp., parent company of Wyeth Research. From 1989 to 1998, he held roles of increasing responsibility at Genetics Institute, Inc., first as head of Research and Development, then as Chief Operating Officer and eventually as President. From 1971 to 1989, Dr. Gage held various positions in research management with Hoffmann-La Roche, Inc., most recently serving as Vice President responsible for U.S. drug discovery. Dr. Gage has served as the Chairman of the Board of Directors of Tetraphase Pharmaceuticals, Inc. since April 2013. Dr. Gage earned a bachelor’s degree in Physics from the Massachusetts Institute of Technology and a Ph.D. in Biophysics from the University of Chicago. Dr. Gage brings to our Board of Directors extensive experience as a public company executive and board member in the pharmaceutical and biotechnology industries and in strategies for bringing breakthrough medicines to approval and commercialization.

What is the salary of Leonard Gage?

As the Independent Chairman of the Board of Cytokinetics Inc, the total compensation of Leonard Gage at Cytokinetics Inc is $247,206. There are 10 executives at Cytokinetics Inc getting paid more, with Robert Blum having the highest compensation of $3,475,980.

How old is Leonard Gage?

Leonard Gage is 77, he's been the Independent Chairman of the Board of Cytokinetics Inc since 2010. There are 1 older and 19 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.

What's Leonard Gage's mailing address?

L's mailing address filed with the SEC is 280, East Grand Avenue, South San Francisco, San Mateo County, California, 94080, United States.

Insiders trading at Cytokinetics Inc

Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi..., and Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.

What does Cytokinetics Inc do?

cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.

Complete history of Leonard Gage stock trades at Cytokinetics Inc, PDL Biopharma Inc, and Tetraphase Pharmaceuticals

Cytokinetics Inc executives and stock owners

Cytokinetics Inc executives and other stock owners filed with the SEC include:

• Robert Blum,
  President, Chief Executive Officer, Director
• Fady Malik,
  Executive Vice President - Research and Development
• Mark Schlossberg,
  Senior Vice President, General Counsel, Secretary
• Ching Jaw,
  Chief Financial Officer, Senior Vice President
• David Cragg,
  Chief Human Resource Officer, Chief Administrative Officer
• Robert I. Blum,
  CEO, Pres & Director
• Dr. Fady Ibraham Malik,
  Exec. VP of R&D
• Mark A. Schlossberg,
  Sr. VP of Legal, Gen. Counsel & Sec.
• Ching W. Jaw,
  Sr. VP & CFO
• David W. Cragg,
  Chief HR & Admin. Officer
• Leonard Patrick Gage,
  Independent Chairman of the Board
• Wendall Wierenga,
  Independent Director
• B. Lynne Parshall,
  Independent Director
• John Henderson,
  Independent Director
• Santo Costa,
  Independent Director
• Sandford Smith,
  Independent Director
• Edward Kaye,
  Independent Director
• Robert Califf,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Diane Weiser,
  IR Contact Officer
• Robert Wong,
  Chief Accounting Officer, Vice President
• Kari K. Loeser J.D.,
  VP & Chief Compliance Officer
• Robert Wong,
  VP & Chief Accounting Officer
• Jeff Lotz,
  VP of Sales & Operations
• Dr. James A. Spudich Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Bradley Paul Morgan,
  SVP Drug Discovery & Early Dev
• Caryn Gordon Mc Dowell,
  GC & Chief Compliance Officer
• Elisabeth Schnieders,
  Sr. VP, Business Development
• L Patrick Gage,
  Director
• Bonnie Charpentier,
  SVP Regulatory & Compliance
• Robert Arthur Harrington,
  Director
• Associates Vi Lp Srb,
  10% owner
• Sung Lee,
  EVP, Chief Financial Officer
• Peter S Roddy,
  SVP Finance & CAO
• Muna Bhanji,
  Director
• Michael Rabson,
  SVP Business Dev/Legal & GC
• A Grant Iii Heidrich,
  Director
• Mark Mcdade,
  Director
• Brett A Pletcher,
  EVP, Chief Legal Officer
• Sharon Barbari,
  Sr. VP, Finance & CFO
• Charles J Homcy,
  Director
• James H Sabry,
  President and CEO
• David J Jr Morgans,
  SVP-Drug Discovery and Dev
• James A Spudich,
  Director
• Michael Schmertzler,
  Director
• Jay K Trautman,
  VP, Technology
• Stephen M Dow,
  Director
• Denise Gilbert,
  Director
• Capital Ltd Portfolio Servi...,
  
• Suisse First Boston/Credit ...,
  
• John Vdomenik Stephen Lbayl...,
  
• William J Rutter,
  Director
• Ixmayfield Ix Management Ll...,
  
• Rosen Vii Affiliates Fund L...,
  10% owner
• Associates Vii Lp Srb,
  10% owner
• Associates Viii Lp Srb,
  10% owner
• Rosen Viii Affiliates Fund ...,
  10% owner
• Rosen Fund Viii Lp Sevin,
  10% owner
• Rosen Fund Vi Lp Sevin,
  10% owner
• Rosen Fund Vii Lp Sevin,
  10% owner
• Rosen Vi Affiliates Fund Lp...,
  10% owner
• Partners L P/Ilbiotechnolog...,
  
• Partners L P/Ilbiotechnolog...,
  
• Andrew Callos,
  EVP, Chief Commercial Officer